Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

812.69 +7.26 (+0.90%)
Official Closing Price Updated: 4:10 PM EDT, Jul 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
99 100 Next >
Eli Lilly Scoops Up Scorpion Therapeutics' Early-Stage Cancer Program For $2.5 Billion
Eli Lilly plans to acquire Scorpion's PI3Kα program for $2.5 billion, reinvesting Mounjaro and Zepbound profits to expand its precision medicines pipeline. 
Via Benzinga
Soricimed Biopharma Appoints Dr. Neil Fleshner as Executive Board Member
Moncton, New Brunswick, Canada--(Newsfile Corp. - January 13, 2025) - Soricimed Biopharma Inc. ("Soricimed"), a clinical-stage biopharmaceutical company focused on... 
Via Newsfile
Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference
JP Morgan highlights mixed sentiment for U.S. large-cap biopharma stocks as advancements in obesity drugs and key product launches shape 2025 outlook. 
Via Benzinga
Medicare To Cover Eli Lilly's Weight Loss Drug Zepbound For Obstructive Sleep Apnea Treatment
Medicare now covers Eli Lilly's Zepbound for obstructive sleep apnea, FDA-approved for obesity and sleep apnea treatment, reducing apnea events by 62.8%. 
Via Benzinga
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
Best Healthcare Stock to Buy: Eli Lilly vs. Novo Nordisk
Via The Motley Fool
How Richard DiMarchi Revolutionized Diabetes Treatment
Antiobesity drugs are amazing people by how fast they melt off pounds. But it's no surprise to Richard DiMarchi. 
Via Investor's Business Daily
3 Stocks to Buy for 2025 That Are Practically Money Machines
Via The Motley Fool
This Promising New Alzheimer's Study Could Unlock a Massive Growth Opportunity for Novo Nordisk and Eli Lilly
Via The Motley Fool
Eli Lilly's Options: A Look at What the Big Money is Thinking
 
Via Benzinga
Investors Look Back at 2024
The S&P 500 had a great year. 
Via The Motley Fool
Topics Stocks
Smart Money Is Betting Big In LLY Options
 
Via Benzinga
$100 Invested In Eli Lilly 15 Years Ago Would Be Worth This Much Today
 
Via Benzinga
Eli Lilly Unusual Options Activity
 
Via Benzinga
Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst
JPMorgan highlights valuation resets for Viking and Structure Therapeutics, citing opportunities in T2D/obesity and competitive clinical data insights. 
Via Benzinga
Israel Englander's Millennium Management Dumps Nvidia, Loads Up On Broadcom — Here's What The $70 Billion Hedge Fund Sees
Israel Englander's Millennium Management has made sweeping adjustments to its portfolio, including a remarkable 91,046.15% increase in Alibaba Group Holding Ltd. (NYSE:BABA) call options and a 94.69%... 
Via Benzinga
Prediction: These 3 Healthcare Stocks Will Soar in 2025
Via The Motley Fool
3 Trends To Watch
Hot topics for 2025 and why. 
Via Talk Markets
Topics Stocks / Equities
New Alphabet CFO Expected To Make Bigger Impact In 2025. Is Google Stock A Buy?
Google stock posted a big gain in 2024 but AI-driven competition in the internet search business and DoJ antitrust cases still loom. 
Via Investor's Business Daily
Jim Cramer Says Lazard Is 'Really Inexpensive,' Recommends Buying This Tech Stock
 
Via Benzinga
Eli Lilly Joins FDA Lawsuit Over Compounded Obesity Drugs, Seeks 'Swift End' And 'To Protect Its Interests'
Eli Lilly moves to defend FDA's tirzepatide shortage resolution amid criticism over supply issues and compounding pharmacy claims. 
Via Benzinga
Topics Lawsuit
Don't Buy Weight-Loss Medication From Unauthorized Sources, UK Health Agency Warns About Risks
The MHRA warns against buying weight-loss medicines illegally, emphasizing health risks and the need for prescriptions from licensed professionals to ensure safety. 
Via Benzinga
The 9 Best Stocks to Buy for 2025
Via The Motley Fool
US Employer Health Costs To Rise In 2025 Fueled By Weight Loss: Report
Eli Lilly's Zepbound is challenging Wegovy in the obesity market, while U.S. health care costs are set to rise 9% in 2025, driven by specialty drugs and inflation. 
Via Benzinga
EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In December 2024 — Where Do Tesla, Nvidia, Quantum Computing Stock Rank?
Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers. 
Via Benzinga
Marjorie Taylor Greene Went Christmas Shopping For Stocks, Here's What She Bought Before Holiday
Marjorie Taylor Greene spent part of Christmas Eve buying stocks according to recent disclosures. Here's what she bought. 
Via Benzinga
Why 2024 Was Great for Stocks—and Why 2025 Could Be Even Better
Stocks soared in 2024, and 2025 could be even stronger. Let's look at key trends, government policies, and sectors poised for growth in the year ahead. 
Via MarketBeat
Topics Economy Energy
Pfizer: 4 Reasons to Buy This Stock
Pharmaceutical giant Pfizer Inc. (NYSE: PFE) stock is trading back down near its pandemic lows. Every time it attempts to climb over the $30 mark, something ca 
Via MarketBeat
Will This Major Pharmaceutical Stock Announce a Stock Split in 2025?
Via The Motley Fool
Billionaire Philippe Laffont Is Selling Artificial Intelligence Champion Nvidia and Piling Into These Two Industry Leaders
Via The Motley Fool
Topics Artificial Intelligence
< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.